The Food and Drug Administration has granted orphan drug designation to a cancer treatment in mid-stage development made by German drug maker 4SC, the company said Tuesday.
Over the years, a fatty liver has become an indicator of obesity and insulin resistance among humans, but researchers have found that people with fatty livers are five times more likely to develop Type 2 diabetes than their healthier counterparts.